Intellect Neurosciences, Inc. Receives Notice of Allowance and Completes Grant Requirements...

Intellect Neurosciences, Inc. Receives Notice of Allowance and Completes Grant
Requirements for Pivotal European Patent Related to Passive Immunization of
Alzheimer's Disease

NEW YORK, April 10 /PRNewswire-FirstCall/ -- Intellect Neurosciences, Inc.
(OTC Bulletin Board: ILNS), announced today that it has obtained a Notice of
Allowance and completed the grant requirements to obtain a European patent
relating to the Company's ANTISENILIN(R) antibodies and products being
developed by the Company for the treatment of Alzheimer's disease. Grant of
the European patent is expected in several weeks. Other patents related to the
ANTISENILIN(R) antibodies have been granted in Japan, China and elsewhere.
Patent applications are pending in the United States. Intellect Neurosciences
is the exclusive assignee of the ANTISENILIN(R) patents, which are based on
the invention of Dr. Daniel Chain, the Company's Chairman and CEO.
Dr. Chain commented: "The use of ANTISENILIN(R) monoclonal antibodies that
specifically target the toxic forms of beta amyloid is at the forefront of the
battle against Alzheimer's disease. In addition to the Company's products in
development, our invention has been applied to promising drug candidates in
clinical development by major pharmaceutical companies."
"Intellect's ANTISENILIN(R) antibody technology incorporates an important
safety feature ("free-end specificity"), meaning that antibodies developed
using the technology are designed to specifically block the neurotoxicity of
beta amyloid, which accumulates in the brains of Alzheimer's patients. The
blocking of the neurotoxicity is achieved by promoting clearance of beta
amyloid away from sites of damage while minimizing the potential for adverse
effects," explained Professor Donald Price, Professor of Pathology, Neurology
and Neuroscience and Founding Director of the Alzheimer's Disease Research
Center at The Johns Hopkins School of Medicine and a member of Intellect's
Scientific Advisory Board. Professor Price added: "Dr. Chain's idea of using
antibodies in this way to reduce amyloid toxicity in the brain has gained
considerable momentum over the past few years and we are currently optimistic
that drugs of this type herald an exciting new era of drug development for
safe and efficacious disease-modifying treatments for this devastating
disease."
About Intellect's Immunotherapy Platforms for Alzheimer's disease
Immunotherapy for Alzheimer's disease involves making an antibody molecule
available to bind to the endogenous beta-amyloid toxin, thus promoting its
clearance away from the brain. This therapeutic outcome can be achieved either
by provoking the patient's immune system to generate such an antibody (active
immunization) or by administering an externally generated antibody (passive
immunization). Both approaches have the potential to slow or arrest disease
progression provided that key safety issues are addressed. Intellect has
incorporated proprietary safety features into its ANTISENILIN(R) and
RECALL-VAX(TM) technology platforms for both passive and active immunization,
respectively. These features and supporting patent position provides the
Company with a strong competitive advantage in this field.
About Alzheimer's disease
Alzheimer's disease, the most common form of dementia, is characterized by
progressive loss of memory and cognition, ultimately leading to complete
debilitation and death. A hallmark feature of Alzheimer's pathology is the
presence of insoluble protein deposits known as beta-amyloid on the surface of
nerve cells, which results from the accumulation of soluble beta-amyloid in
the brain. The effects of the disease are devastating to the patients as well
as the caregivers, with significant associated health care costs. It is
estimated that there are over 12 million people suffering from Alzheimer's
disease in the in the developed countries with the number increasing also in
developing countries as the global population ages. Currently marketed drugs
transiently affect some of the symptoms of the disease, but there are no drugs
on the market today that slow or arrest the progression of the disease. These
symptomatic drugs are projected to generate approximately $4 billion in sales
by 2008, indicating both the size of the market and the demand for effective
treatment beyond symptomatic improvements.
About Intellect Neurosciences, Inc.
Intellect Neurosciences, Inc. is a biopharmaceutical company engaged in
the discovery and development of disease-modifying therapeutic agents for the
treatment and prevention of Alzheimer's disease and other disorders. The
company has a broad proprietary immunotherapy platform for both passive and
active immunization against Alzheimer's disease. Also, Intellect has recently
completed Phase I clinical trials for OXIGON(TM), a unique antioxidant and
anti-amyloid compound that has potential to treat Alzheimer's disease and
other disorders. For additional information, please visit
http://www.intellectns.com, or contact:
Elliot Maza, JD, CPA
President & Chief Financial Officer
Intellect Neurosciences, Inc.
7 West 18th Street, 9th Floor
New York, NY 10011, USA
Tel: 212-448-9300

Safe Harbor Statement Regarding Forward-Looking Statements
The statements in this release and oral statements made by representatives
of Intellect relating to matters that are not historical facts (including
without limitation those regarding future performance or financial results,
the timing or potential outcomes of research collaborations or clinical
trials,
any market that might develop for any of Intellect's product candidates and
the sufficiency of Intellect's cash and other capital resources) are forward-
looking statements that involve risks and uncertainties, including, but not
limited to, the likelihood that actual performance or results could materially
differ, that future research will prove successful, the likelihood that any
product in the research pipeline will receive regulatory approval in the
United States or abroad, or Intellect's ability to fund such efforts with or
without partners. Intellect undertakes no obligation to update any of these
statements. Readers are cautioned not to place undue reliance on these
forward-looking statements, which speak only as to the date hereof.
Accordingly any forward-looking statements should be read in conjunction with
the additional risks and uncertainties detailed in Intellect's filings with
the Securities and Exchange Commission, including those factors discussed
under the caption "Risk Factors" in Intellect's Annual Report on Form 10-KSBA
(file no. 1-10615) filed on October 19, 2007, and our Quarterly Report on Form
10-QSB for the quarter ended September 30, 2007, filed on December 10, 2007
(file no. 1-10615), and for the quarter ended December 31, 2007, filed on
February 19, 2007.
SOURCE Intellect Neurosciences, Inc.

Elliot Maza, JD, CPA, President & Chief Financial Officer of Intellect
Neurosciences, Inc., +1-212-448-9300